Entries by Mithra Pharmaceuticals

Mithra Signs LSA for Commercialization of Myring™ in France, Poland and United Kingdom

Mithra grants license to Zentiva for commercialization of its vaginal contraceptive ring in three key European markets Consolidation of commercial roll-out in Europe with 17 countries already under license Production ongoing at Mithra CDMO for upcoming European commercial launches Liege, Belgium, 06 July 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated […]

Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 23 June 2020 – 17:45 CEST –In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, Mithra Pharmaceuticals SA (the “Company” or “Mithra”) announces the following information, following the […]

Notice of Extraordinary Shareholders’ Meeting on 22th July 2020 Regarding Proposed Warrant Plans

Liege, Belgium, 19 June 2020 – 17:45 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces the publication of the invitation to its Extraordinary General Shareholders’ Meeting (EGM) that will be held on Wednesday July 22 2020 at 2:00 PM (CET) in Flémalle 57 rue de l’Expansion (Belgium). The agenda […]

Mithra Successfully Raises EUR 65 Million By Means of a Private Placement via an Accelerated Bookbuild Offering

Liège, Belgium, 18 June 2020 20:30 CEST – Mithra Pharmaceuticals SA (the “Company” or “Mithra”), a company specialized in Women’s Health (Euronext Brussels: MITRA), announces today that it successfully raised an amount of EUR 65.0 million in gross proceeds by means of a private placement via an accelerated bookbuild offering of 3,421,052 new shares (being […]

Mithra Launches Capital Increase By Means of a Private Placement via an Accelerated Bookbuild Offering and Provides an Update on its Financing Strategy

Launch of a capital increase of approximately EUR 55 million by means of a private placement via an accelerated bookbuild offering Loan of EUR 20 million secured, in addition to the recent capital commitment agreement with LDA for up to EUR 50 million Last building blocks in the Company’s financing strategy in becoming a commercial […]

Mithra Signs LSA for Commercialization of Tibelia® in Liechtenstein and Switzerland

Mithra grants license to Spirig Healthcare (Stada Group) for commercialization of its hormone treatment Tibelia® in Liechtenstein and Switzerland Tibelia® is currently marketed in about 30 countries through existing license and supply agreements Liege, Belgium, 11 June 2020 – 7:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces it […]

Mithra Signs License and Supply Agreement with Mayne Pharma for Commercialization of Estelle in Australia

Consolidation of partnership with Mayne Pharma for commercialization of the combined oral contraceptive E4/DRSP (Estelle®) in Australia Mithra eligible for milestone and license fees of up to EUR 3.5 million Preparation ongoing for the commercial launch of Mithra’s oral contraceptive in the U.S. and Australia, targeted for H1 and H2 2021 respectively Liege, Belgium, 28 […]

Mithra Launches a Research Programme on Estetrol’s Effect in Covid-19 Treatment

Women are more likely than men to be spared by Covid-19, with less severe infections and lower mortality rates Protective role of estrogen against human coronaviruses already demonstrated during the SARS infection, and currently being tested in the U.S. among hospitalized patients Mithra plans to develop a research program to study Estetrol (E4) mechanism of […]